A detailed history of Candriam S.C.A. transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 294,624 shares of EWTX stock, worth $9.68 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
294,624
Previous 329,000 10.45%
Holding current value
$9.68 Million
Previous $5.93 Million 32.71%
% of portfolio
0.05%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.88 - $29.5 $545,890 - $1.01 Million
-34,376 Reduced 10.45%
294,624 $7.86 Million
Q1 2024

May 03, 2024

BUY
$9.25 - $19.97 $194,250 - $419,370
21,000 Added 6.82%
329,000 $6 Million
Q4 2023

Feb 14, 2024

BUY
$5.51 - $12.1 $55,100 - $121,000
10,000 Added 3.36%
308,000 $3.37 Million
Q4 2022

Feb 13, 2023

BUY
$7.58 - $11.08 $818,640 - $1.2 Million
108,000 Added 56.84%
298,000 $2.66 Million
Q3 2022

Nov 10, 2022

BUY
$8.08 - $13.58 $1.54 Million - $2.58 Million
190,000 New
190,000 $1.87 Million

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $2.08B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.